Loading…
vTv Therapeutics Inc. is projected to rise to $37.71 by 2027, a +13% move from its current price of $33.44. VTVT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $32.45 | $33.46 | $34.50 | +0.07% |
| Jul 13 | $32.07 | $33.49 | $34.97 | +0.14% |
| Jul 14 | $31.78 | $33.51 | $35.33 | +0.20% |
| Jul 15 | $31.54 | $33.53 | $35.65 | +0.27% |
| Jul 16 | $31.33 | $33.55 | $35.93 | +0.34% |
| Jul 17 | $31.15 | $33.58 | $36.19 | +0.41% |
| Jul 18 | $30.98 | $33.60 | $36.44 | +0.48% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.98 | $33.60 | $36.44 | +0.48% |
| Week 2 | $30.10 | $33.76 | $37.86 | +0.96% |
| Week 3 | $29.48 | $33.92 | $39.03 | +1.44% |
| Week 4 | $28.98 | $34.08 | $40.08 | +1.92% |
| Week 5 | $28.57 | $34.25 | $41.05 | +2.41% |
| Week 6 | $28.21 | $34.41 | $41.97 | +2.90% |
| Week 7 | $27.90 | $34.57 | $42.84 | +3.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
The company has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
vTv Therapeutics Inc. trades under the symbol VTVT and currently displays a price of $35.04 per share. Its market capitalization stands at $138.01M, and the stock is ranked 4060 by market cap/size metrics.
The long-range forecast outlines a rising price trajectory, with 2026 average around $35.04 and a path that extends to multi-hundred dollar levels by 2050. The 2026 forecast shows a neutral sentiment, while subsequent years shift toward a bullish outlook as averages climb toward $58.64 by 2030 and to $336.28 by 2050.
A major floor 20.3% below — a decisive break under it would weaken the trend.
The nearest floor, 9.0% below — buyers have tended to step in here.
The nearest ceiling, 12.6% above — a clean break opens room to run.
A major ceiling 23.1% above — clearing it would confirm fresh momentum.
Key VTVT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VTVT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.04 | Sell | $34.07 | Sell |
| MA 10 | $34.97 | Sell | $34.46 | Sell |
| MA 20 | $34.53 | Sell | $34.45 | Sell |
| MA 50 | $33.70 | Sell | $34.40 | Sell |
| MA 100 | $35.25 | Sell | $34.13 | Sell |
| MA 200 | $32.58 | Buy | $31.72 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.58 | Neutral |
| Stoch RSI (14) | 1.33 | Buy |
| CCI (20) | -59.01 | Neutral |
| Williams %R (14) | -98.81 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | -5.19 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 1.19 | Buy |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 28.61 | Buy |
| Momentum (10) | -3.33 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 33.36 | Buy |
| ADX (14) | 8.28 | Neutral |
| ATR (14) | 1.00 | Info |
The 30-day technical picture is bullish. The RSI(14) sits at 60, with the 50-day simple moving average at $34.02 and the 200-day simple moving average at $31.52, indicating a constructive intermediate trend.
Support is at $30.44 and resistance at $38.43, framing a near-term range. The stated 30-day trading range runs from $27.85 to $44.08, reflecting moderate volatility within a bullish backdrop.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.02 | $33.44 | $44.91 | 0% | Neutral | |
| $29.68 | $37.71 | $50.89 | +13% | Neutral | |
| $28.54 | $37.43 | $52.62 | +12% | Neutral | |
| $33.30 | $44.83 | $65.06 | +34% | Bullish | |
| $37.38 | $51.52 | $76.78 | +54% | Bullish | |
| $42.05 | $59.21 | $90.31 | +77% | Bullish | |
| $50.21 | $72.12 | $112.32 | +116% | Bullish | |
| $50.05 | $73.25 | $116.24 | +119% | Bullish | |
| $49.36 | $73.55 | $118.75 | +120% | Bullish | |
| $52.68 | $79.84 | $130.99 | +139% | Bullish | |
| $77.00 | $126.21 | $221.39 | +277% | Bullish | |
| $138.67 | $260.62 | $503.64 | +679% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $29.02 | $33.44 | $40.05 | +0.00% |
| August 2026 | $29.41 | $34.84 | $42.46 | +4.18% |
| September 2026 | $29.81 | $35.58 | $43.90 | +2.13% |
| October 2026 | $28.93 | $34.77 | $43.35 | -2.27% |
| November 2026 | $28.72 | $34.72 | $43.66 | -0.16% |
| December 2026 | $29.15 | $35.43 | $44.91 | +2.04% |
Click any year to see its month-by-month VTVT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VTVT is projected to trade between $29.02 and $44.91, averaging $33.44 — a potential gain of 0% from today's $33.44. A consolidation phase looks the most probable path here.
vTv Therapeutics Inc.'s 2027 outlook centres on $37.71, within a $29.68 to $50.89 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. Price action looks broadly range-bound.
By 2028, VTVT could reach as high as $52.62, with a base case around $37.43 and support toward $28.54 — roughly +12% from $33.44. A consolidation phase looks the most probable path here.
Expect VTVT to range from $33.30 to $65.06 through 2029. The $44.83 average target implies a +34% move from current prices. That is up +20% on the projected 2028 average. Momentum favours further upside here.
The VTVT price prediction for 2030 points to an average of $51.52 (low $37.38, high $76.78) — a potential gain of +54% on today's $33.44. Buyers look set to stay in control over this stretch.
In 2031, VTVT is projected to trade between $42.05 and $90.31, averaging $59.21 — a potential gain of +77% from today's $33.44. That is up +15% on the projected 2030 average. Momentum favours further upside here.
vTv Therapeutics Inc.'s 2032 outlook centres on $72.12, within a $50.21 to $112.32 range. That is up +22% on the projected 2031 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, VTVT could reach as high as $116.24, with a base case around $73.25 and support toward $50.05 — roughly +119% from $33.44. Momentum favours further upside here.
Expect VTVT to range from $49.36 to $118.75 through 2034. The $73.55 average target implies a +120% move from current prices. That is up 0% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The VTVT price prediction for 2035 points to an average of $79.84 (low $52.68, high $130.99) — a potential gain of +139% on today's $33.44. Momentum favours further upside here.
In 2040, VTVT is projected to trade between $77.00 and $221.39, averaging $126.21 — a potential gain of +277% from today's $33.44. That is up +58% on the projected 2035 average. Buyers look set to stay in control over this stretch.
vTv Therapeutics Inc.'s 2050 outlook centres on $260.62, within a $138.67 to $503.64 range. That is up +106% on the projected 2040 average. That marks a +679% change versus current levels. Momentum favours further upside here.
Investing $1,000 in VTVT today (≈ 29.904306 VTVT) could be worth
$7,793.81
+$6,793.81 (+679%) by 2050 · US Dollar
Based on the average projected VTVT price of $260.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VTVTwould be worth at today's price.
$1,000 invested in VTVT on Jul 10, 2025 (≈ 57.142857 VTVT) would be worth
$1,910.86
+$910.86 (+91.1%) today · 1.91× · US Dollar
Based on a VTVT entry price of $17.5 vs. today's $33.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.4 | $944.63 | -5.5% |
| 1 month ago | $30.44 | $1,098.55 | +9.9% |
| 3 months ago | $36.56 | $914.66 | -8.5% |
| 6 months ago | $34.12 | $980.07 | -2.0% |
| 1 year ago | $17.5 | $1,910.86 | +91.1% |
| All time (5.0y) ago | $82.8 | $403.86 | -59.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VTVT forecast.
Our base-case forecast reaches $67.00 around 2032.
Implied market cap at $67.00: $263.89M
Over the multi-year horizon, the forecast shows continued upside with rising averages and strong returns. The 2027 forecast average is $39.63 with a 13.1% ROI and neutral sentiment, followed by 2028 at $42.15 (20.3% ROI) and 2029 at $49.60 (41.5% ROI) as bullish momentum grows.
By 2030, the forecast calls for an average of $58.64 with a 67.3% ROI and bullish sentiment. The longer-horizon view extends to 2040 with an average of $161.88 and a 362% ROI, and to 2050 with an average of $336.28 and an 859.7% ROI, both labeled bullish.
These numbers reflect estimates of potential upside under the stated forecast framework. They are not guaranteed and are subject to uncertainty inherent in equity and biotech developments.
Tap a question to reveal the answer.
2030 forecast: min $41.32, avg $58.64, max $90.19; ROI 67.3%; sentiment BULLISH.
Forecasts show sentiment turning bullish from 2028 onward, with rising averages: 2027 avg $39.63 (ROI 13.1%), 2028 avg $42.15 (ROI 20.3%), 2029 avg $49.60 (ROI 41.5%), 2030 avg $58.64 (ROI 67.3%), and 2031 avg $71.01 (ROI 102.7%). These are estimates, not guarantees.
Yes. The 2031 max forecast is $112.02, and the 2032 max is $137.74, indicating a path that could exceed $100 by 2031 according to the forecast.
$27.85 to $44.08.
Current price is $35.04 and market cap is $138.01M.
vTv Therapeutics Inc. Community Discussion
0Share your vTv Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.